-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CureVac has signed a contract with WACKER to produce its vaccine candidate, CVnCoV
WACKER recently announced that it has signed a contract with CureVac to produce its vaccine candidate, CVnCoV
.
According to the preliminary agreement, WACKER will produce the active ingredients
for CVnCoV in accordance with Good Manufacturing Practice (GMP) at its Amsterdam site in the first half of 2021.
Preparations for production start-up, technology transfer and commissioning are already underway
.
WACKER's Amsterdam site expects to produce more than 100 million CureVac vaccine
kits per year.
The site can also be expanded to meet growing market demands
in the future.
Over the past few months, WACKER has increased its investment in the site to enable it to also produce mRNA-based vaccines
.